GTMB 7 - Gene Therapy & Molecular Biology

More documents

Recommendations

Info

Sanlioglu et al: Adenovirus mediated gene therapy for prostate carcinomaFigure 3. Adenovirus mediated clinical gene therapy modalities for prostate. The types of clinical gene therapy modalities for prostateare represented as percentages in a pie graph in order to better appreciate the contribution of each treatment modality.AcknowledgmentsThis work is supported by Akdeniz UniversityScientific Research Project Administration DivisionGrants (#2002.01.0122.06, #2002.01.0122.07 and#2002.01.0200.005 to Dr. Salih Sanlioglu).ReferencesAbe K, Kurakin A, Mohseni-Maybodi M, Kay B, and Khosravi-Far R (2000) The complexity of TNF-related apoptosisinducingligand. Ann N Y Acad Sci 926, 52-63.Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M,Iruela-Arispe ML, and Wu L (2002) Visualization ofadvanced human prostate cancer lesions in living mice by atargeted gene transfer vector and optical imaging. Nat Med8, 891-897.Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S, and LiouHC (2000) Phosphatidylinositol 3-kinase and NF-κ B/Rel areat the divergence of CD40-mediated proliferation andsurvival pathways. J Immunol 165, 3860-3867.Batra RK, Guttridge DC, Brenner DA, Dubinett SM, BaldwinAS, and Boucher RC (1999) IκBα gene transfer is cytotoxicto squamous-cell lung cancer cells and sensitizes them totumor necrosis factor-α-mediated cell death. Am J RespirCell Mol Biol 21, 238-245Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC,Dunning P, Christofferson R, Mulligan RC, Taylor GA, KuoCJ, and Zetter BR (2002) Gene therapy of prostate cancerwith the soluble vascular endothelial growth factor receptorflk1. Cancer Biol Ther 1, 548-553.Beg AA, and Baltimore D (1996) An essential role for NF-κB inpreventing TNF-α-induced cell death. Science 274, 782-784.Beresford SA, Davies MA, Gallick GE, and Donato NJ (2001)Differential effects of phosphatidylinositol-3/Akt-kinaseinhibition on apoptotic sensitization to cytokines in LNCaPand PCc-3 prostate cancer cells. J Interferon Cytokine Res21, 313-322.Bernard D, Quatannens B, Vandenbunder B, and Abbadie C(2001) Rel/NF-κB transcription factors protect against tumornecrosis factor (TNF)-related apoptosis-inducing ligand(TRAIL)-induced apoptosis by up-regulating the TRAILdecoy receptor DcR1. J Biol Chem 276, 27322-27328.Boring CC, Squires TS, Tong T, and Montgomery S (1994)Cancer statistics, 1994. CA Cancer J Clin 44, 7-26.Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-BurowBM, Beckman BS, and McLachlan JA (2000) PI3-K/AKTregulation of NF-κB signaling events in suppression of TNFinducedapoptosis. Biochem Biophys Res Commun 271,342-345.Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, and Dong Z(2001) Adenovirus-mediated interferon-β gene therapysuppresses growth and metastasis of human prostate cancerin nude mice. Cancer Gene Ther 8, 497-505.Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, andHood L (1997) Death receptor 5, a new member of the TNFRfamily, and DR4 induce FADD- dependent apoptosis andactivate the NF-κB pathway. Immunity 7, 821-830.Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J,Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D,Scott S, Stephens J, Karpf DB, Henderson DR, and Yu DC(2001) CV706, a prostate cancer-specific adenovirus variant,in combination with radiotherapy produces synergisticantitumor efficacy without increasing toxicity. Cancer Res61, 5453-5460Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ,Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK,Thompson TC, Butler EB, and Aguilar-Cordova E (2001)Enhanced therapeutic effect of HSV-tk+GCV gene therapyand ionizing radiation for prostate cancer. Mol Ther 3, 536-542.Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, andGallick GE (2002) Adenoviral-mediated expression ofMMAC/PTEN inhibits proliferation and metastasis of humanprostate cancer cells. Clin Cancer Res 8, 1904-1914.Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ,McConkey D, Yung WK, and Steck PA (1999) Regulation ofAkt/PKB activity, cellular growth, and apoptosis in prostatecarcinoma cells by MMAC/PTEN. Cancer Res 59, 2551-2556.Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, SmithCA, and Goodwin RG (1997) The novel receptor TRAIL-R4induces NF-κB and protects against TRAIL-mediatedapoptosis, yet retains an incomplete death domain.Immunity 7, 813-820.Demarchi F, Verardo R, Varnum B, Brancolini C, and SchneiderC (2001) Gas6 anti-apoptotic signaling requires NF-κ Bactivation. J Biol Chem 276, 31738-31744.Devi GR (2002) Prostate cancer: status of current treatments andemerging antisense- based therapies. Curr Opin Mol Ther4, 138-148.DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R,Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R,Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y,128
Gene Therapy and Molecular Biology Vol 7, page 129Henderson DR, Carducci MA, Nelson WG, and Simons JW(2001) A phase I trial of CV706, a replication-competent,PSA selective oncolytic adenovirus, for the treatment oflocally recurrent prostate cancer following radiation therapy.Cancer Res 61, 7464-7472Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, KerrDJ, Harris PA, Mountain A, and Wrighton CJ (2001)Combined adenovirus-mediated nitroreductase gene deliveryand CB1954 treatment: a well-tolerated therapy forestablished solid tumors. Mol Ther 3, 233-240Do LV, Do TM, Smith R, and Parker RG (2002) PostoperativeRadiotherapy for Carcinoma of the Prostate: Impact on BothLocal Control and Distant Disease-Free Survival. Am J ClinOncol 25, 1-8.Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, WangJ, Timme TL, Aguilar-Cordova E, and Thompson TC (2002)Gene therapy for prostate cancer: toxicological profile offour HSV-tk transducing adenoviral vectors regulated bydifferent promoters. Prostate Cancer Prostatic Dis 5, 316-325Ehlert JE, and Kubbutat MH (2001) Apoptosis and its relevancein cancer therapy. Onkologie 24, 433-440.Elzey BD, Siemens DR, Ratliff TL, and Lubaroff DM (2001)Immunization with type 5 adenovirus recombinant for atumor antigen in combination with recombinant canarypoxvirus (ALVAC) cytokine gene delivery induces destructionof established prostate tumors. Int J Cancer 94, 842-849Farkas A, Schneider D, Perrotti M, Cummings KB, and WardWS (1998) National trends in the epidemiology of prostatecancer, 1973 to 1994: evidence for the effectiveness ofprostate-specific antigen screening. Urology 52, 444-448;discussion 448-449.Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY,Thomas WD, Nguyen T, and Hersey P (2001) The role ofNF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166, 5337-5345.Franklin J, Hislop J, Flynn A, and McArdle CA (2003)Signalling and anti-proliferative effects mediated bygonadotrophin- releasing hormone receptors after expressionin prostate cancer cells using recombinant adenovirus. JEndocrinol 176, 275-284.Freytag SO, Khil M, Stricker H, Peabody J, Menon M,DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D,Brown S, Barton K, Lu M, Aguilar-Cordova E, and Kim JH(2002a) Phase I study of replication-competent adenovirusmediateddouble suicide gene therapy for the treatment oflocally recurrent prostate cancer. Cancer Res 62, 4968-4976Freytag SO, Paielli D, Wing M, Rogulski K, Brown S,Kolozsvary A, Seely J, Barton K, Dragovic A, and Kim JH(2002b) Efficacy and toxicity of replication-competentadenovirus-mediated double suicide gene therapy incombination with radiation therapy in an orthotopic mouseprostate cancer model. Int J Radiat Oncol Biol Phys 54,873-885Furuhata S, Ide H, Miura Y, Yoshida T, and Aoki K (2003)Development of a prostate-specific promoter for genetherapy against androgen-independent prostate cancer. MolTher 7, 366-374.Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, Koropatnick J,Chin JL, Moussa M, and Xuan JW (2002) Prostate targeting:PSP94 gene promoter/enhancer region directed prostatetissue-specific expression in a transgenic mouse prostatecancer model. Gene Ther 9, 1589-1599Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C,Yu-Lee LY, and Lin SH (2003) Expression and purificationof the angiogenesis inhibitor 16-kDa prolactin fragment frominsect cells. Protein Expr Purif 28, 252-258.Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A,Slaga TJ, and Budunova IV (2002a) The role of IKK inconstitutive activation of NF-κB transcription factor inprostate carcinoma cells. J Cell Sci 115, 141-151.Gasparian AV, Yao YJ, Lu J, Yemelyanov AY, Lyakh LA, SlagaTJ, and Budunova IV (2002b) Selenium compounds inhibit IκB kinase (IKK) and nuclear factor- κB (NF-κB) in prostatecancer cells. Mol Cancer Ther 1, 1079-1087.Giri D, Ozen M, and Ittmann M (2001) Interleukin-6 is anautocrine growth factor in human prostate cancer. Am JPathol 159, 2159-2165.Greenlee RT, Hill-Harmon MB, Murray T, and Thun M (2001)Cancer statistics, 2001. CA Cancer J Clin 51, 15-36.Griffith TS, and Broghammer EL (2001) Suppression of tumorgrowth following intralesional therapy with TRAILrecombinant adenovirus. Mol Ther 4, 257-266.Griffith TS, Chin WA, Jackson GC, Lynch DH, and Kubin MZ(1998) Intracellular regulation of TRAIL-induced apoptosisin human melanoma cells. J Immunol 161, 2833-2840.Griffith TS, and Lynch DH (1998) TRAIL: a molecule withmultiple receptors and control mechanisms. Curr OpinImmunol 10, 559-563.Grumet SC, and Bruner DW (2000) The identification andscreening of men at high risk for developing prostate cancer.Urol Nurs 20, 15-18, 23-14, 46.Gustin JA, Maehama T, Dixon JE, and Donner DB (2001) ThePTEN tumor suppressor protein inhibits tumor necrosisfactor- induced nuclear factor κB activity. J Biol Chem 276,27740-27744.Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA, and ChenSH (2002) A novel bystander effect involving tumor cellderivedFas and FasL interactions following Ad.HSV-tk andAd.mIL-12 gene therapies in experimental prostate cancer.Gene Ther 9, 511-517.Hatano E, and Brenner DA (2001) Akt protects mousehepatocytes from TNF-α- and Fas-mediated apoptosisthrough NK-κB activation. Am J Physiol GastrointestLiver Physiol 281, G1357-1368.Hemmati PG, Gillissen B, von Haefen C, Wendt J, Starck L,Guner D, Dorken B, and Daniel PT (2002) Adenovirusmediatedoverexpression of p14(ARF) induces p53 and Baxindependentapoptosis. Oncogene 21, 3149-3161.Herr I, and Debatin KM (2001) Cellular stress response andapoptosis in cancer therapy. Blood 98, 2603-2614.Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, FangB, Lowe SL, Norris JS, Meyn RE, and McDonnell TJ (2002)A recombinant adenovirus expressing wild-type Bax inducesapoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol Ther 1, 163-167Horowitz J (1999) Adenovirus-mediated p53 gene therapy:overview of preclinical studies and potential clinicalapplications. Curr Opin Mol Ther 1, 500-509.Hsieh CL, and Chung LW (2001) New prospectives of prostatecancer gene therapy: molecular targets and animal models.Crit Rev Eukaryot Gene Expr 11, 77-120.Hsieh CL, Yang L, Miao L, Yeung F, Kao C, Yang H, Zhau HE,and Chung LW (2002) A novel targeting modality toenhance adenoviral replication by vitamin D(3) in androgenindependenthuman prostate cancer cells and tumors. CancerRes 62, 3084-3092.Hyer ML, Sudarshan S, Kim Y, Reed JC, Dang JY, SchwartzDA, and Norris JS (2002) Downregulation of c-FLIPSensitizes DU145 Prostate Cancer Cells to Fas- MediatedApoptosis. Cancer Biol Ther 1, 401-406.Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, andNorris JS (2003) Quantification and characterization of thebystander effect in prostate cancer cells following129
Page 7 and 8:
Instructions to authors:Gene Therap
Page 9:
Please submit an electronic version
Page 12:
103-111 ResearchArticle113-133 Revi
Page 17 and 18:
Gene Therapy and Molecular Biology
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77:
Page 80 and 81:
Epperly et al: Late injection of Mn
Page 82 and 83:
Epperly et al: Late injection of Mn
Page 84 and 85:
Goldberg-Cohen et al: Regulation of
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Gascón-Irún et al: Gene therapy a
Page 92 and 93: Gascón-Irún et al: Gene therapy a
Page 106 and 107: Suzuki et al: Regulation of the Sp/
Page 114 and 115: Li et al: MET amplification in live
Page 116 and 117: Li et al: MET amplification in live
Page 118 and 119: Chavakis et al: Leukocyte adhesion
Page 128 and 129: Sanlioglu et al: Adenovirus mediate
Page 150 and 151: George et al: Gene therapy for vasc
Page 168 and 169: Zhang et al: Angiogenic Gene Therap
Page 182 and 183: Xu et al: G-CSF receptor-mediated S
Page 188 and 189: Burek et al: Calcium induced cell d
Page 190 and 191: Burek et al: Calcium induced cell d
Page 192 and 193:
Burek et al: Calcium induced cell d
Page 194 and 195:
Burek et al: Calcium induced cell d
Page 196 and 197:
David et al: Current status and fut
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Stoll et al: The role of EBV and ge
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Maruyama et al: Kidney-targeted pla
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Kren et al: Hepatocyte-targeted del
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Zeng: PRL-3 as a target for cancer
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Latchman: Protective effect of heat
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Cai et al: Lung cancer gene therapy
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309:
show all

GTMB 7 - Gene Therapy & Molecular Biology

Create successful ePaper yourself

Delete template?

Save as template?